Research area · Intestinal research

KPV peptide research: what the mouse and cell studies measured

If you searched for “peptides for gut health”, this page covers what has been studied in that research area. KPV is a peptide people often ask about in connection with the gut. The studies in our register are in mice and in human cells in a dish. BPC-157 also has older human trials known only from conference abstracts.

  • Evidence grade or review status for every compound
  • Sources listed on every page
  • US and sport status, dated
2 compoundsPreclinical
Updated Nov 2026Dated on every page
KPV BPC-157
The research so far

What has been studied

In 2008, researchers gave KPV by mouth to mice with chemically induced colitis and also studied it in human intestinal epithelial and T-cell lines. These are mouse and cell results, not evidence of an effect in people. [1]

A phase II trial of BPC-157 in ulcerative colitis is known only from a 2005 conference abstract; FDA staff found its data inadequate to support efficacy and safety. [2] [8]

Evidence grades

How far the research has gone

Pick a compound to see the highest rung reached, from cell study to approval.

Cell studies
—
Animal studies
—
Human pilot / case series
—
Controlled human trials
—
Regulatory approval
—
Highest rung reached
—

How we grade evidence

What the research does not show

Saying what we don't know is part of the evidence.

Any effect of KPV in people: the studies in our register are mouse and cell studies.

Where it stands legally

As of November 2026. See the full tracker and the changelog.

CompoundFDA approval503A compounding (2026)WADA (2026 List)
KPVNot approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetNot named; S0 covers unapproved substances
BPC-157Not approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetProhibited (S0, named)

Worth knowing

Research use only

None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.

What research use only means

No doses, ever

We publish no doses, protocols, or cycles for people, on any page.

Why we publish no doses

How we grade evidence

Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.

Evidence grades

Questions people ask

Has KPV been tested in people?

Not in our register. The studies we hold are mouse and cell studies, so we make no statement about effects in people.

What does the October 2026 HHS policy say about KPV?

HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians compounding KPV under ten conditions, including a patient-specific prescription, while the list of permitted ingredients goes through rulemaking. The Federal Register notice calls the policy a draft; it is not binding and not an approval.

Sources

  1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID 18061177. pubmed.ncbi.nlm.nih.gov/18061177/
  2. Klicek R, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats. J Pharmacol Sci. 2008;108(1):7–17. PMID 18818478. pubmed.ncbi.nlm.nih.gov/18818478/
  3. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
  4. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting page, 23–24 July 2026: agenda, voting questions and FDA briefing (no minutes posted as of 17 November 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  5. World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
  6. U.S. Department of Health and Human Services. Enforcement discretion policy, Appendix B: peptide identities and justifications, October 2026 (records the July 2026 committee outcome for each of the six peptides). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  7. Federal Register 91 FR 68526, 30 October 2026. Notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (the notice calls the policy a draft). www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  8. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances (pp. 27, 40–43). www.fda.gov/media/193343/download

Start with the evidence

Every page sourced and dated, including what the research does not show.

Open the research library
Written by 6AM Research. Drafted with AI from published studies, trial registries, and regulator documents, plus press reports where marked. Every page lists its sources and is dated. Editorial policy · Corrections
Education only. Nothing here is medical advice or describes use in people. Research use only